Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 3Phase 2 2Phase 3 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 3Colorectal Neoplasms 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 22Paclitaxel 17Capecitabine 16fludarabine 15Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × adagrasib × Clear all
NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04418661 2025-05-29

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Sanofi

Phase 1/2 Terminated
65 enrolled 32 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT05375994 2025-05-18

RAMP204

Verastem, Inc.

Phase 1/2 Active not recruiting
85 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡